BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $12,187 | +86.9% | 164,262 | +108.8% | 0.19% | +46.5% |
| Q4 2022 | $6,522 | -99.9% | 78,688 | +302.8% | 0.13% | +7.5% |
| Q3 2022 | $5,548,000 | +95.6% | 19,535 | +138.7% | 0.12% | +62.2% |
| Q2 2022 | $2,837,000 | +995.4% | 8,183 | +1536.6% | 0.07% | +1750.0% |
| Q4 2021 | $259,000 | -55.3% | 500 | -58.3% | 0.00% | -55.6% |
| Q3 2021 | $580,000 | -84.1% | 1,200 | -85.2% | 0.01% | -87.0% |
| Q2 2021 | $3,654,000 | +1102.0% | 8,117 | +919.7% | 0.07% | +1050.0% |
| Q1 2021 | $304,000 | -74.7% | 796 | -79.0% | 0.01% | -82.4% |
| Q4 2020 | $1,202,000 | -19.8% | 3,785 | -37.4% | 0.03% | -47.7% |
| Q3 2020 | $1,498,000 | +51.2% | 6,046 | +15.6% | 0.06% | -27.0% |
| Q1 2020 | $991,000 | +144.1% | 5,228 | +182.7% | 0.09% | +394.4% |
| Q4 2019 | $406,000 | -69.6% | 1,849 | -71.1% | 0.02% | -52.6% |
| Q2 2019 | $1,335,000 | +53.8% | 6,403 | -16.8% | 0.04% | +111.1% |
| Q2 2016 | $868,000 | +162.2% | 7,700 | +120.0% | 0.02% | +125.0% |
| Q1 2016 | $331,000 | -19.5% | 3,500 | -14.6% | 0.01% | -38.5% |
| Q1 2015 | $411,000 | -20.5% | 4,100 | -26.8% | 0.01% | -27.8% |
| Q4 2014 | $517,000 | -23.3% | 5,600 | -22.2% | 0.02% | -25.0% |
| Q3 2014 | $674,000 | – | 7,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |